Articles with public access mandates - Prof. Wojciech Jurczak, MD, PhDLearn more
Not available anywhere: 8
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
S Stilgenbauer, B Eichhorst, J Schetelig, S Coutre, JF Seymour, T Munir, ...
The lancet oncology 17 (6), 768-778, 2016
Mandates: US National Institutes of Health
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
AR Mato, NN Shah, W Jurczak, CY Cheah, JM Pagel, JA Woyach, ...
The Lancet 397 (10277), 892-901, 2021
Mandates: US National Institutes of Health
Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies
RR Furman, JC Byrd, RG Owen, SM O’Brien, JR Brown, P Hillmen, ...
Leukemia 35 (11), 3201-3211, 2021
Mandates: US National Institutes of Health
Mosunetuzumab monotherapy in elderly/unfit PTS with first‐line diffuse large B‐cell lymphoma (DLBCL): safety and efficacy remain promising with durable complete responses
AJ Olszewski, A Avigdor, S Babu, I Levi, H Eradat, U Abadi, H Holmes, ...
Hematological Oncology 39, 2021
Mandates: Government of Spain
ABCL-500 Longer Follow-Up Reaffirms Subcutaneous Epcoritamab Induces Deep and Durable Complete Remissions in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Updated …
Y Karimi, H Ghesquieres, W Jurczak, CY Cheah, MR Clausen, ...
Clinical Lymphoma Myeloma and Leukemia 23, S438, 2023
Mandates: US National Institutes of Health
Zanubrutinib safety/tolerability profile and comparison with ibrutinib profile in B‐cell malignancies: Post hoc analysis of a large clinical trial safety database.
JR Brown, B Eichorst, P Ghia, W Jurczak, BS Kahl, N Lamanna, T Robak, ...
Hematological Oncology 41, 2023
Mandates: National Natural Science Foundation of China
CC‐99282 plus R‐CHOP in patients (pts) with previously untreated aggressive B‐cell lymphoma (a‐BCL): early safety and efficacy results from a phase 1b study.
J Munoz, M Hoffmann, J Westin, TP Vassilakopoulos, AM García‐Sancho, ...
Hematological Oncology 41, 2023
Mandates: US National Institutes of Health
TG‐1701, A SELECTIVE BRUTON TYROSINE KINASE (BTK) INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH UBLITUXIMAB AND UMBRALISIB (U2) IN PATIENTS WITH B‐CELL MALIGNANCIES
CY Cheah, W Jurczak, M Lasica, N Wickham, T Wróbel, J Walewski, ...
Hematological Oncology 39, 2021
Mandates: National Medical Research Council, Singapore
Available somewhere: 35
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
ML Wang, S Rule, P Martin, A Goy, R Auer, BS Kahl, W Jurczak, ...
New England Journal of Medicine 369 (6), 507-516, 2013
Mandates: US National Institutes of Health
PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma
AK Gopal, BS Kahl, S De Vos, ND Wagner-Johnston, SJ Schuster, ...
New England Journal of Medicine 370 (11), 1008-1018, 2014
Mandates: US National Institutes of Health
Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma
JM Connors, W Jurczak, DJ Straus, SM Ansell, WS Kim, A Gallamini, ...
New England Journal of Medicine 378 (4), 331-344, 2018
Mandates: US National Institutes of Health
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
S Horwitz, OA O'Connor, B Pro, T Illidge, M Fanale, R Advani, NL Bartlett, ...
The Lancet 393 (10168), 229-240, 2019
Mandates: US National Institutes of Health, National Institute for Health Research, UK …
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase …
JP Sharman, M Egyed, W Jurczak, A Skarbnik, JM Pagel, IW Flinn, ...
The Lancet 395 (10232), 1278-1291, 2020
Mandates: US National Institutes of Health
Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non–germinal center B-cell diffuse large B-cell lymphoma
A Younes, LH Sehn, P Johnson, PL Zinzani, X Hong, J Zhu, C Patti, ...
Journal of Clinical Oncology 37 (15), 1285-1295, 2019
Mandates: US National Institutes of Health
Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study
OA O'Connor, S Horwitz, T Masszi, A Van Hoof, P Brown, J Doorduijn, ...
Journal of Clinical Oncology 33 (23), 2492-2499, 2015
Mandates: US National Institutes of Health
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
ML Wang, KA Blum, P Martin, A Goy, R Auer, BS Kahl, W Jurczak, ...
Blood, The Journal of the American Society of Hematology 126 (6), 739-745, 2015
Mandates: US National Institutes of Health
Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial
JC Byrd, P Hillmen, P Ghia, AP Kater, A Chanan-Khan, RR Furman, ...
Journal of clinical oncology 39 (31), 3441-3452, 2021
Mandates: US National Institutes of Health
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
F Morschhauser, H Tilly, A Chaidos, P McKay, T Phillips, S Assouline, ...
The Lancet Oncology 21 (11), 1433-1442, 2020
Mandates: US National Institutes of Health
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial
M Wang, S Rule, PL Zinzani, A Goy, O Casasnovas, SD Smith, G Damaj, ...
The Lancet 391 (10121), 659-667, 2018
Mandates: US National Institutes of Health
Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial
S Stilgenbauer, B Eichhorst, J Schetelig, P Hillmen, JF Seymour, S Coutre, ...
Journal of Clinical Oncology 36 (19), 1973-1980, 2018
Mandates: National Institute for Health Research, UK
Publication and funding information is determined automatically by a computer program